第一创业证券承销保荐有限责任公司 关于凯莱英医药集团（天津）股份有限公司 使用暂时闲置募集资金进行现金管理的核查意见 第一创业证券承销保荐有限责任公司（以下简称"一创投行"或"保荐机构"） 作为凯莱英医药集团（天津）股份有限公司（以下简称"凯莱英"或"公司"）的保 荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证券交易所股票上市规 则》、《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》、《上市公司募集资金监管规则》等法律和规范性文件的要求，对凯莱英医 药集团（天津）股份有限公司使用暂时闲置募集资金进行现金管理情况进行了审 慎核查。具体情况如下： 一、募集资金基本情况 经中国证券监督管理委员会证监许可[2020]1912 号文《关于核准凯莱英医药 集团（天津）股份有限公司非公开发行股票的批复》核准，公司于 2020 年 9 月 向特定投资者发行人民币普通股（A 股）股票 10,178,731.00 股，每股发行价为 227.00 元/股，募集资金总额为人民币 2,310,571,937.00 元，扣除承销费用（不含 税）32,696,772.70 元，公司实际收到募集资金人民币 ...

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of September 15, 2025 [1] Core Insights - The trend of Chinese innovative drugs going overseas continues, with a focus on selective opportunities. The report highlights that the global pharmaceutical transaction volume reached 456 deals in the first half of 2025, a 32% year-on-year increase, with upfront payments totaling $11.8 billion, a 136% surge, and total transaction value hitting $130.4 billion, up 58% year-on-year [2] - The report emphasizes the promising clinical data from Chinese innovative drugs presented at the World Lung Cancer Conference, particularly in the ADC (Antibody-Drug Conjugate) field, showcasing significant efficacy advantages [3] - The report discusses the potential of small nucleic acid drugs and innovative delivery systems, indicating new market opportunities arising from strategic collaborations between Chinese companies and multinational corporations [4] - The CXO (Contract Research Organization) sector is expected to gradually recover, with a notable increase in orders anticipated in the third quarter of 2025, driven by improved innovation environments and funding from license-out transactions [5] - The 2025 medical insurance negotiation and commercial insurance innovative drug directory work has commenced, with a focus on orphan drugs and breakthrough treatment varieties [6] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry underperformed the CSI 300 index by 1.75% in the past week, with a recent one-month increase of 3.32%, lagging behind the CSI 300 by 5.81% [22][26] - The medical device sector showed the highest weekly increase of 2.23%, while the chemical pharmaceutical sector experienced a decline of 2.57% [31] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical industry index's current PE (TTM) stands at 40.60, above the five-year historical average of 31.60 [46] - The report notes that the pharmaceutical sector has shown a 15.06% increase over the past three months, outperforming the CSI 300 by 16.11% [43] 3. Recent Research Achievements - The report outlines recent research achievements by the Huaxin pharmaceutical team, including various in-depth and commentary reports on innovative drug developments and market trends [50] 4. Recent Industry Policies and News - The report details recent policy updates from the National Healthcare Security Administration regarding the 2025 drug directory adjustments and the approval of new drug applications [52][55]

Market Overview - On September 15, the medical services sector rose by 1.58%, led by Zhaoyan New Drug, while the Shanghai Composite Index closed at 3860.5, down 0.26% [1] - The Shenzhen Component Index closed at 13005.77, up 0.63% [1] Top Performers - Zhaoyan New Drug (603127) closed at 41.65, with a gain of 10.01% and a trading volume of 597,900 shares, amounting to a transaction value of 2.418 billion [1] - Boteng Co., Ltd. (300363) closed at 28.59, up 9.21%, with a trading volume of 571,200 shares, totaling 1.633 billion [1] - Kanglong Chemical (300759) closed at 35.90, increasing by 6.37%, with a trading volume of 895,600 shares, amounting to 3.178 billion [1] Underperformers - Jukang Life (300143) closed at 12.19, down 5.21%, with a trading volume of 245,900 shares, totaling 306 million [2] - Digital Human (835670) closed at 17.13, down 3.22%, with a trading volume of 55,800 shares, amounting to 9.562 million [2] - BGI Genomics (300676) closed at 53.20, down 3.11%, with a trading volume of 152,700 shares, totaling 81.5 million [2] Capital Flow - The medical services sector saw a net inflow of 502 million from institutional investors, while retail investors experienced a net outflow of 423 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional buying contrasting with retail selling [2] Individual Stock Capital Flow - Kailaiying (002821) had a net inflow of 1.90 billion from institutional investors, while retail investors saw a net outflow of 1.87 billion [3] - Kanglong Chemical (300759) experienced a net inflow of 184 million from institutional investors, with retail investors seeing a net outflow of 1.51 billion [3] - Jiuzhou Pharmaceutical (603456) had a net inflow of 47.19 million from institutional investors, while retail investors experienced a net outflow of 81.89 million [3]

从基金十大重仓股角度 数据显示，嘉实基金旗下1只基金重仓凯莱英。嘉实医疗保健股票（000711）二季度持有股数38.71万 股，占基金净值比例为4.14%，位居第八大重仓股。根据测算，今日浮盈赚取约228.78万元。 嘉实医疗保健股票（000711）成立日期2014年8月13日，最新规模8.25亿。今年以来收益41.32%，同类 排名748/4222；近一年收益53.88%，同类排名1833/3802；成立以来收益131.9%。 9月15日，凯莱英涨5.27%，截至发稿，报117.99元/股，成交12.47亿元，换手率3.43%，总市值425.46亿 元。 资料显示，凯莱英医药集团(天津)股份有限公司位于天津经济技术开发区第七大街71号，成立日期1998 年10月7日，上市日期2016年11月18日，公司主营业务涉及提供CMO医药外包服务。主营业务收入构成 为：小分子CDMO解决方案76.19%，新兴服务23.71%，其他0.10%。 截至发稿，郝淼累计任职时间6年244天，现任基金资产总规模36.52亿元，任职期间最佳基金回报 183.83%， 任职期间最差基金回报-28.36%。 风险提示：市场有风险，投 ...

截至发稿，姚炜累计任职时间6年281天，现任基金资产总规模4.56亿元，任职期间最佳基金回报 65.93%， 任职期间最差基金回报-38.1%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，中海基金旗下1只基金重仓凯莱英。中海医药混合A（000878）二季度增持7.39万股，持有股 数22.43万股，占基金净值比例为6.25%，位居第六大重仓股。根据测算，今日浮盈赚取约132.58万元。 中海医药混合A（000878）成立日期2014年12月17日，最新规模2.3亿。今年以来收益29.89%，同类排 名2686/8246；近一年收益41.89%，同类排名3946/8054；成立以来收益135.66%。 中海医药混合A（000878）基金经理为姚炜。 9月15日，凯莱英涨5.27%，截至发稿，报117.99元/股，成交12.45亿元，换手率3.43%，总市值425.46亿 元。 资料显示，凯莱英医药集团(天津)股份有限公司位于天津经济技术开 ...

Group 1 - CRO concept stocks experienced a rise in early trading, with notable increases in share prices for companies such as 康龙化成 (up 8.11% to HKD 25.58), 昭衍新药 (up 6.27% to HKD 24.76), 药明生物 (up 4.88% to HKD 38.26), and 凯莱英 (up 4.33% to HKD 101.3) [1] - On September 12, the National Medical Products Administration of China announced a new policy to complete the review and approval of clinical trial applications for innovative drugs within 30 working days, effective immediately [1] - The new policy applies to clinical trial applications for innovative drugs that meet one of three specified criteria, further accelerating the approval process for certain applications [1] Group 2 - Concerns have arisen in the market regarding the U.S. administrative draft, with 华福证券 noting that the "Biological Safety Act" has undergone 10 changes since the end of 2023 [2] - The stock price response of representative CXO companies to the progress of the "Biological Safety Act" has shown a trend of desensitization, with current stock prices recovering and reaching new highs [2] - The ongoing BD wave in China's innovative drug sector reflects the advantages of talent resources, research efficiency, and cost, indicating that U.S. policies will not significantly impact the competitiveness of China's innovative drug industry [2]

Group 1: Macro and Strategy - The report highlights the impact of the Federal Reserve's quantitative easing (QE) policies on U.S. Treasury yields, indicating that while QE provides liquidity, its long-term effects significantly lower yields [8][9]. - The report outlines four phases of the Federal Reserve's bond purchasing history, detailing the transition from traditional monetary policy to QE during the 2008 financial crisis and the COVID-19 pandemic [9][10]. - Recent economic data indicates a potential rebound in the bond market, with expectations for improved performance following the release of economic growth data on September 15 [11][12]. Group 2: Industry and Company Insights - The semiconductor industry, particularly the analog chip sector, is expected to see growth, with global market sizes projected to increase by 3.3% and 5.1% in 2025 and 2026, respectively [16][17]. - Domestic companies in the analog chip market are anticipated to benefit from increased demand in industrial, automotive, and AI applications, with significant potential for domestic market share growth [17][18]. - The renewable energy sector, particularly wind power, is experiencing favorable pricing outcomes, with competitive bidding results indicating strong investment returns for wind projects [19][20]. - Agricultural products are projected to enter a bullish cycle, with expectations for rising prices in beef and milk, driven by supply dynamics and market recovery [21][22][23]. - The report notes that the company Golden Meat Industry has seen a significant increase in profits from its beef and lamb business, despite challenges in its pig farming segment [35][36]. Group 3: Company-Specific Developments - Daikin Heavy Industries has secured a large contract worth approximately 1.25 billion yuan for offshore wind turbine foundations, which is expected to positively impact its financial performance in 2026 [24][25]. - Kelaiying, a leading CDMO in China, is expanding its service offerings and is projected to achieve steady revenue growth, with a forecasted revenue of 66.8 billion yuan in 2025 [26][28]. - Aibo Medical has reported a significant increase in net profit driven by high-end artificial crystal products, with a 30% quarter-on-quarter growth in the second quarter [29][30][31]. - Bluko is launching new products to enhance its IP portfolio, which is expected to drive revenue growth, particularly in the lower-priced market segment [33][34].

9月11日，凯莱英跌5.86%，截至发稿，报104.50元/股，成交2.82亿元，换手率0.86%，总市值376.82亿 元。 资料显示，凯莱英医药集团(天津)股份有限公司位于天津经济技术开发区第七大街71号，成立日期1998 年10月7日，上市日期2016年11月18日，公司主营业务涉及提供CMO医药外包服务。主营业务收入构成 为：小分子CDMO解决方案76.19%，新兴服务23.71%，其他0.10%。 从凯莱英十大流通股东角度 数据显示，华宝基金旗下1只基金位居凯莱英十大流通股东。华宝中证医疗ETF（512170）二季度减持 109.21万股，持有股数664.67万股，占流通股的比例为1.93%。根据测算，今日浮亏损失约4320.35万 元。 华宝中证医疗ETF（512170）成立日期2019年5月20日，最新规模261.47亿。今年以来收益19.93%，同 类排名2253/4222；近一年收益43.62%，同类排名2230/3798；成立以来收益17.52%。 华宝中证医疗ETF（512170）基金经理为胡洁。 截至发稿，胡洁累计任职时间12年334天，现任基金资产总规模843.4亿元，任职期间最佳基 ...

Core Viewpoint - The company is actively expanding its capabilities in the peptide CDMO sector, particularly in the weight loss area, and is well-positioned for future growth despite potential regulatory challenges in the U.S. market [1][2] Group 1: Peptide Capacity and Market Demand - The company's peptide CDMO business is primarily driven by the rapidly growing weight loss sector, with participation in over ten molecular collaborations [1] - Projects in the weight loss field are expected to enter the PPQ (Process Performance Qualification) stage next year, indicating a positive trajectory for capacity utilization [1] - The company’s capacity expansion plans are based not only on current utilization rates but also on anticipated future commercialization needs from clients [1] Group 2: Order Backlog and Revenue Growth - As of the disclosure date of the 2025 semi-annual report, the company has a total order backlog of nearly $1.1 billion, providing a solid foundation for annual performance growth [1] - The European market has shown exceptional performance, with revenue reaching 548 million yuan in the first half of the year, representing a year-on-year growth of over 200% [1] Group 3: Global Market Strategy and Regulatory Concerns - The company is focused on accelerating global market expansion and emerging business layouts to strengthen its competitive advantage in the chemical small molecule and peptide CDMO sectors [2] - Concerns regarding potential strict regulations on Chinese pharmaceuticals by the U.S. are deemed to have limited impact on the company's global business expansion [1] - The company aims to continuously enhance its overall competitiveness while closely monitoring external policy impacts [1]

证券研究报告 | 2025年09月11日 凯莱英（002821.SZ） 小分子CDMO行业引领，新兴业务扬帆起航 公司研究 · 深度报告 医药生物 · 医药研发外包 投资评级：优于大市（首次覆盖） 0755-81982723 pengsiyu@guosen.com.cn S0980521060003 证券分析师：陈曦炳 0755-81982939 chenxibing@guosen.com.cn S0980521120001 证券分析师：彭思宇 联系人：凌珑 021-60375401 linglong@guosen.com.cn 请务必阅读正文之后的免责声明及其项下所有内容 1 投资建议 n 凯莱英：全球领先、技术驱动型的一站式CDMO综合服务商 凯莱英成立于1998年，是中国第二大化学药物CDMO企业。公司以化学小分子CDMO业务为基石，逐步拓展业务边界，技术创新能力行业领先， 研发费用率长期居于行业领先水平，服务辉瑞、默沙东等全球超1100家客户。 n 小分子业务：基石业务稳健 小分子CDMO作为公司的业务根基，依托连续流化学(CFCT)、酶催化等核心技术，持续攻克高难度分子合成壁垒，巩固在抗肿瘤、抗病毒 ...